CVS blows past estimates, hikes guidance as insurance unit continues to improve
CVS Health on Wednesday blew past second-quarter earnings and revenue estimates and raised its 2026 guidance, as its insurance unit...
Biotech and Pharmaceuticals
Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer Inc. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Wednesday, March...
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player in the...
Humana tops quarterly estimates, maintains profit outlook as medical costs stay in line
Cheng Xin | Getty Images News | Getty ImagesHumana on Wednesday reported second-quarter results that topped estimates, as the health...
What to know about testosterone replacement therapy as the U.S. military plans to test troops
US Secretary of Defense Pete Hegseth speaks during a press briefing at the Pentagon in Washington, DC, on April 8,...
UnitedHealth blows past estimates, hikes earnings outlook as it reins in costs
UnitedHealth Group on Thursday posted second-quarter earnings that blew past estimates and raised its full-year profit outlook, as the company...
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Michael Siluk | UCG | Universal Images Group | Getty ImagesLosing weight with GLP-1 drugs is only half the battle....
AstraZeneca stock dives 9% after heart drug trial misses target
Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease failed to meet...
French biotech stock soars 34% after new data on experimental medicine
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease,...
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity...
America can't get enough of protein. The dairy industry can't keep up
Whitebalance.space | E+ | Getty ImagesAmerica's "protein-maxxing" obsession is stressing the dairy industry.Whey protein concentrate, once considered a cheap byproduct...
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in...
Estrogen patches are hard to find, and it may not be resolved any time soon
Woman applying estrogen patch during hormone therapy.Halfpoint Images | Moment | Getty ImagesEstrogen patches are in short supply as demand...
What this biotech's volatile stock price tells you about the weight loss market right now
Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher...
Centene to offer buyouts to some employees as health insurer cuts costs
Sheldon Cooper | Lightrocket | Getty ImagesCentene said it offered buyouts to some employees on Monday, as the health insurer...
Drugmakers race to find a place in the next wave of obesity drugs
Drugmakers are only months into introducing GLP-1 pills and navigating huge changes in how patients pay for weight-loss drugs. Even...
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Novo Nordisk and Eli Lilly took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare...
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Jacob Van Naarden is busy. In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next...
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled as much 32% after it reported fresh data on its lead asset, a drug...
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Thomas Fuller | Lightrocket | Getty ImagesReplimune plans to resubmit its melanoma drug to the Food and Drug Administration for...
